- Home
- AIM vs VRME Comparison
AIM vs VRME Comparison
Compare AIM & VRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- VRME
- Stock Information
- Founded
- AIM 1966
- VRME 1999
- Country
- AIM United States
- VRME United States
- Employees
- AIM N/A
- VRME N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- VRME EDP Services
- Sector
- AIM Health Care
- VRME Technology
- Exchange
- AIM Nasdaq
- VRME Nasdaq
- Market Cap
- AIM 15.9M
- VRME 14.6M
- IPO Year
- AIM N/A
- VRME N/A
- Fundamental
- Price
- AIM $0.22
- VRME $1.00
- Analyst Decision
- AIM Strong Buy
- VRME Buy
- Analyst Count
- AIM 2
- VRME 1
- Target Price
- AIM $3.00
- VRME $1.50
- AVG Volume (30 Days)
- AIM 295.4K
- VRME 27.0K
- Earning Date
- AIM 11-15-2024
- VRME 11-12-2024
- Dividend Yield
- AIM N/A
- VRME N/A
- EPS Growth
- AIM N/A
- VRME N/A
- EPS
- AIM N/A
- VRME N/A
- Revenue
- AIM $190,000.00
- VRME $25,259,000.00
- Revenue This Year
- AIM N/A
- VRME $1.14
- Revenue Next Year
- AIM $1,086.80
- VRME $10.56
- P/E Ratio
- AIM N/A
- VRME N/A
- Revenue Growth
- AIM N/A
- VRME N/A
- 52 Week Low
- AIM $0.21
- VRME $0.90
- 52 Week High
- AIM $0.62
- VRME $2.45
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- VRME 30.55
- Support Level
- AIM $0.24
- VRME $0.90
- Resistance Level
- AIM $0.27
- VRME $1.32
- Average True Range (ATR)
- AIM 0.02
- VRME 0.11
- MACD
- AIM -0.00
- VRME -0.03
- Stochastic Oscillator
- AIM 7.49
- VRME 20.92
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About VRME VerifyMe Inc.
VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.